Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the phase 3 solstice trial: data at 52 weeks post-maribavir treatment initiation

Overall mortality at 52 weeks post-maribavir treatment initiation in this sub-cohort of patients from the SOLSTICE trial was lower than that previously reported for similar populations treated with conventional therapies for R/R cytomegalovirus infection.